Factors associated with adherence to ursodeoxycholic acid or placebo in patients after bariatric surgery

Ursodeoxycholic acid (UDCA) reduces symptomatic gallstone disease after Roux-en-Y gastric bypass (RYGB). The beneficial effect of UDCA is reduced by poor adherence. We aimed to identify factors associated with poor adherence to UDCA or placebo after bariatric surgery. Outpatient clinic and department for bariatric surgery in three hospitals in the Netherlands. Patients in the multicenter, double-blind, randomized, placebo-controlled UPGRADE trial were assessed for adherence to 900 mg UDCA or placebo for 6 months through a pill count, inquiries during follow-up, and a questionnaire. Poor adherence was defined as the usage of